English  |  正體中文  |  简体中文  |  2823020  
???header.visitor??? :  30201508    ???header.onlineuser??? :  941
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"liao b c"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 76-100 of 131  (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2020-07-21T06:09:03Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Chen K.-Y.; Tsai T.-H.; Ho C.-C.; WEI-YU LIAO; Yang C.-Y.; Yang C.-Y.;Wei-Yu Liao;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yu C.-J.; Yang J.C.-H.; Shih J.-Y.; Lin C.-C.; Lee J.-H.; Hsu W.-H.; Liao B.-C.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.
臺大學術典藏 2020-07-21T05:40:29Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.; Lee J.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Ching-Yao Yang;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Su K.-Y.;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; CHING-YAO YANG; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.
臺大學術典藏 2020-06-30T08:09:57Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Lin S.-Y.;Yang C.-Y.;Liao B.-C.;Ho C.-C.;Liao W.-Y.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Hsu W.-H.;Kang-Yi Su;Chang Y.-L.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.;Yu C.-J.; Lin S.-Y.; Yang C.-Y.; Liao B.-C.; Ho C.-C.; Liao W.-Y.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Hsu W.-H.; KANG-YI SU; Chang Y.-L.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.; Yu C.-J.
臺大學術典藏 2020-06-30T08:09:52Z Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Liu Y.-N.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Liao B.-C.;Hsu C.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-06-30T08:09:51Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y.;Liao W.-Y.;Ho C.-C.;Chen K.-Y.;Tsai T.-H.;Hsu C.-L.;Kang-Yi Su;Chang Y.-L.;Wu C.-T.;Hsu C.-C.;Liao B.-C.;Hsu W.-H.;Lee J.-H.;Lin C.-C.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; KANG-YI SU; Chang Y.-L.; Wu C.-T.; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏 2020-05-26T09:27:09Z Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study Chih-Hsin Yang;Liao B.-C; Liao B.-C; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:27:03Z First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments Liao B.-C;Lin C.-C;Chih-Hsin Yang; Liao B.-C; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:56Z Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma Lai M.-S.;Chih-Hsin Yang;Cheng A.-L;Chen K.-H;Lai C.-L;Kuo R.N;Lin Z.-Z;Shau W.-Y;Chen H.-M;Shao Y.-Y;Liao B.-C; Liao B.-C; Shao Y.-Y; Chen H.-M; Shau W.-Y; Lin Z.-Z; Kuo R.N; Lai C.-L; Chen K.-H; Cheng A.-L; CHIH-HSIN YANG; Lai M.-S.
臺大學術典藏 2020-05-26T09:26:55Z Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:55Z Treating patients with ALK-positive non-small cell lung cancer: Latest evidence and management strategy Chih-Hsin Yang;Shih J.Y;Lin C.C;Liao B.C; Liao B.C; Lin C.C; Shih J.Y; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:52Z Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Chih-Hsin Yang;Yu C.-J;Shih J.-Y;Ho C.-C;Chang C.-H;Chen Y.-F;Lin C.-C;Lee J.-H;Liao B.-C; Liao B.-C; Lee J.-H; Lin C.-C; Chen Y.-F; Chang C.-H; Ho C.-C; Shih J.-Y; Yu C.-J; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:51Z Cytotoxic chemotherapy as first-line therapy for advanced non-small-cell lung cancer in Taiwan: Daily practice Lai M.-S.;Cheng A.-L;Chiang C.-J;Chen H.-M;Chih-Hsin Yang;Lee H.-S;Liao B.-C;Shao Y.-Y;Liang Y.-H; Liang Y.-H; Shao Y.-Y; Liao B.-C; Lee H.-S; CHIH-HSIN YANG; Chen H.-M; Chiang C.-J; Cheng A.-L; Lai M.-S.
臺大學術典藏 2020-05-26T09:26:47Z 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs Chih-Hsin Yang;Yu C.-J;Chang Y.-C;Shih J.-Y;Ho C.-C;Lee Y.-F;Lin S.-Y;Lin C.-C;Bai Y.-Y;Liao B.-C; Liao B.-C; Bai Y.-Y; Lin C.-C; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:43Z Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors Chih-Hsin Yang;Lee J.-H;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; Lee J.-H; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:36Z Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy Chih-Hsin Yang;Lee J.-H;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; Lee J.-H; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:34Z Tumor PD-L1 expression and clinical outcomes in advanced-stage non-small cell lung cancer patients treated with nivolumab or pembrolizumab: Real-world data in Taiwan Yu C.-J.;Chih-Hsin Yang;Shih J.-Y;Lin C.-C;Lee J.-H;Chang Y.-L;Su K.-Y;Hsu W.-H;Hsu C.-L;Tsai T.-H;Chen K.-Y;Liao W.-Y;Ho C.-C;Liao B.-C;Yang C.-Y;Lin S.-Y; Lin S.-Y; Yang C.-Y; Liao B.-C; Ho C.-C; Liao W.-Y; Chen K.-Y; Tsai T.-H; Hsu C.-L; Hsu W.-H; Su K.-Y; Chang Y.-L; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J.
臺大學術典藏 2020-05-26T09:26:29Z Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors Yang P.-C.;Chih-Hsin Chih-Hsin Yang;Yu C.-J;Chang Y.-C;Shih J.-Y;Ho C.-C;Lee Y.-F;Lin S.-Y;Lin C.-C;Lee J.-H;Bai Y.-Y;Liao B.-C; Liao B.-C; Bai Y.-Y; Lee J.-H; Lin C.-C; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; Chih-Hsin CHIH-HSIN YANG; Yang P.-C.
臺大學術典藏 2020-05-26T09:26:28Z Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Chih-Hsin Yang;Lin C.-C;Liao B.-C; Liao B.-C; Lin C.-C; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:23Z Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients Liao B.-C;Griesing S;Chih-Hsin Yang; Liao B.-C; Griesing S; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:17Z Exon 16?�Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M?�Positive Non?�Small Cell Lung Cancer Hsu C.-C;Liao B.-C;Liao W.-Y;Markovets A;Stetson D;Thress K;Chih-Hsin Yang; Hsu C.-C; Liao B.-C; Liao W.-Y; Markovets A; Stetson D; Thress K; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:17Z Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors Yang C.-Y;Liao W.-Y;Ho C.-C;Chen K.-Y;Tsai T.-H;Hsu C.-L;Su K.-Y;Chang Y.-L;Wu C.-T;Hsu C.-C;Liao B.-C;Hsu W.-H;Lee J.-H;Lin C.-C;Shih J.-Y;Chih-Hsin Yang;Yu C.-J.; Yang C.-Y; Liao W.-Y; Ho C.-C; Chen K.-Y; Tsai T.-H; Hsu C.-L; Su K.-Y; Chang Y.-L; Wu C.-T; Hsu C.-C; Liao B.-C; Hsu W.-H; Lee J.-H; Lin C.-C; Shih J.-Y; CHIH-HSIN YANG; Yu C.-J.
臺大學術典藏 2020-05-25T07:35:25Z First-line management of EGFR-mutated advanced lung adenocarcinoma: Recent developments Liao B.-C; Chia-Chi Lin; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:20Z Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer Liao B.-C; Chia-Chi Lin; Yang J.C.-H.
臺大學術典藏 2020-05-25T07:35:19Z Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Yang J.C.-H.; Yu C.-J; Shih J.-Y; Ho C.-C; Chang C.-H; Chen Y.-F; Chia-Chi Lin; Lee J.-H; Liao B.-C
臺大學術典藏 2020-05-25T07:35:18Z 151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs Liao B.-C; Bai Y.-Y; Chia-Chi Lin; Lin S.-Y; Lee Y.-F; Ho C.-C; Shih J.-Y; Chang Y.-C; Yu C.-J; Yang J.

Showing items 76-100 of 131  (6 Page(s) Totally)
<< < 1 2 3 4 5 6 > >>
View [10|25|50] records per page